iGEM 2021 — Team TokyoTech

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:TokyoTech/Notebook

# Notebook

Document the dates you worked on your project. This should be a detailed account of the work done each day for your project.

### What should this page have?

* Chronological notes of what your team is doing.
* Brief descriptions of daily important events.
* Pictures of your progress.
* Mention who participated in what task.

### Inspiration

You can see what others teams have done to organize their notes:

* [2018 Munich](https://2018.igem.org/Team%3AMunich/Notebook)
* [2019 Georgia State](https://2019.igem.org/Team%3AGeorgia_State/Notebook)
* [2019 Newcastle](https://2019.igem.org/Team%3ANewcastle/Notebook)
* [2020 IISER Pune India](https://2020.igem.org/Team%3AIISER-Pune-India/Notebook)
* [2020 Lund](https://2020.igem.org/Team%3ALund/Notebook)
* [2020 NOVA LxPortugal](https://2020.igem.org/Team%3ANOVA_LxPortugal/Notebook)
* [2020 RDFZ China](https://2020.igem.org/Team%3ARDFZ-China/NoteBook)

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:TokyoTech/Engineering

# [![teamlogo](https://static.igem.org/mediawiki/2021/d/d1/T--tokyotech--logo.jpg)](https://2021.igem.org/Team%3ATokyoTech)

* [HOME](https://2021.igem.org/Team%3ATokyoTech)
* [Project](https://2021.igem.org/Team%3ATokyoTech/Background)
  + [Background](https://2021.igem.org/Team%3ATokyoTech/Background)
  + [Despriciton](https://2021.igem.org/Team%3ATokyoTech/Description)
  + [Contribution](https://2021.igem.org/Team%3ATokyoTech/Contribution)
  + [Implementation](https://2021.igem.org/Team%3ATokyoTech/Implementation)
* [Wet Lab](https://2021.igem.org/Team%3ATokyoTech/Design)
  + [Design](https://2021.igem.org/Team%3ATokyoTech/Design)
  + [Engineering](https://2021.igem.org/Team%3ATokyoTech/Engineering)
  + [Parts](https://2021.igem.org/Team%3ATokyoTech/Parts)
* [Dry Lab](https://2021.igem.org/Team%3ATokyoTech/Model)
  + [Modeling](https://2021.igem.org/Team%3ATokyoTech/Model)
* [Human Practices](https://2021.igem.org/Team%3ATokyoTech/Human_Practices)
  + [Specialists](https://2021.igem.org/Team%3ATokyoTech/Specialists)
  + [Education](https://2021.igem.org/Team%3ATokyoTech/Communication)
  + [Team Building](https://2021.igem.org/Team%3ATokyoTech/TeamBuilding)
  + [Deliver Class](https://2021.igem.org/Team%3ATokyoTech/DeliveryClass)
  + [BioSafety](https://2021.igem.org/Team%3ATokyoTech/BioSafety)
* [Team](https://2021.igem.org/Team%3ATokyoTech/Team)
  + [Members](https://2021.igem.org/Team%3ATokyoTech/Team)
  + [Judging Form](https://igem.org/2021_Judging_Form?id=4019)
  + [Collaborations](https://2021.igem.org/Team%3ATokyoTech/Collaborations)
  + [Attributions](https://2021.igem.org/Team%3ATokyoTech/Attributions)

Engineering Success

![](https://static.igem.org/mediawiki/2021/1/1b/T--TokyoTech--Engineering_Success.png)

## Our Engineering Design Cycle

**Design**
After deciding on the project theme, we needed to decide on the enzyme to use. Based on the structure and bio-metabolism of cinnamaldehyde, we thought that a synthetic route from L-phenylalanine would be practical. The enzymes that synthesize cinnamaldehyde had been registered by previous teams, but based on the paper[1], we attempted to replace one of the enzymes with a different enzyme in this project.

**Build**
We decided to express the three enzymes required for cinnamaldehyde synthesis on a single plasmid. Since the genes of each enzyme are relatively large (more than 1000), we decided to use a homologous assembly such as the HiFi assembly (NEB Inc.). The design was done by Benchling and synthesized by IDT Inc.
We also performed diffusion modeling of cinnamaldehyde to determine the amount of cinnamaldehyde synthesized in the vicinity of antimicrobial target, *S. mutans*.

**Test**
The three enzyme genes designed for cinnamaldehyde synthesis were synthesized by HiFi assembly and confirmed by inverse PCR. There were some difficulties in this, such as vector preparation. In addition, the efficiency of transformation into lactic acid bacteria was also measured by the shuttle vector pMG36e.
Diffusion modeling, on the other hand, was performed by extending the famous Fick's diffusion equation to three dimensions.

**Learn**
We transformed *E. coli* beforehand because experiments showed that the transformation efficiency of *L.lactis* was low. In modeling, it indicated that synthesis 1.0×10-11[mol/s] of cinnamaldehyde per recombinant lactic acid bacteria was desirable.

**Future**
Transformation of cinnamaldehyde into *L. lactis*. The extraction of cinnamaldehyde and the measurement conditions by HPLC have been prepared.

## Details of the experiment

**Antimicrobial activity assay**

To evaluate antimicrobial activity of cinnamaldehyde and bacteriocin against *Streptococcus mutans*, we determined Minimum Inhibitory Concentration(MIC) of them.

**Broth Dilution Method**

 We made two-fold dilutions of antimicrobial agents\* on the 96-well plate and added TSB and overnight culture of *S.mutans* and *Listeria Monocytogenes*(Control) each well.

\*We purchased cinnamaldehyde from Wako, and bacteriocin was purified from broth of H99 and quantified concentration by OPA.

Fig. 1 MIC of cinnamaldehyde and bacteriocin

![](https://static.igem.org/mediawiki/2021/2/2f/T--TokyoTech--MIC.jpg)

The critical concentrations for antimicrobial activity were 3-fold dilution for cinnamaldehyde and the initial concentration for bacteriocin.
\*n was added no antibacterial substances as a negative control.

Table.1 MIC of cinnamaldehyde and bacteriocin

|  | Initial concentration | MIC against *S.mutans* |
| Cinnamaldehyde | 4.00 mg/mL | 0.500 mg/mL |
| Bacteriocin | 0.062 mM | 0.062 mM |

**Measurement of transformation efficiency**

 To confirm that our backbone plasmid works in *L.lactis*, we measured transformation efficiency. *Lactococcus lactis* subsp. cremoris NZ9000 was harvested in MRS medium and collected by centrifugation. Collected cells are washed with HEPES,sucrose buffer and suspended. The pMG36e was transformed into *L.lactis* by electroporation at 1500V/2000V/2500V. Transformants are spread on MRS agar plates with and without 4 µg/mL erythromycin.
Colonies could be seen on the plates of 1500 V. Colony forming units was calculated as follows.

\[
\ 88 CFU / (17.6\_{ng / \mu L} \times 10\_{\mu L} \times 10^{-3} ) \times \frac{400}{200} = 1000 CFU/\mu g
\]

Fig. 2 Transformation efficiency

![](https://static.igem.org/mediawiki/2021/d/db/T--TokyoTech--transformant.jpg)

No colonies were observed at 2000 V and 2500 V, but colonies gradually appeared over 2-6 days at 1500 V.

**Gene cloning**

Before building the entire system as a whole, we constructed three functional plasmid, Cinnamaldehyde biosynthesis gene plasmid, Bacteriocin biosynthesis gene plasmid and Glucan-binding protein C expression plasmid.

**Bacterial strains and plasmids**

*E. coli* DH5α was used for primary host of protein expression and production of antibacterial compounds. *Lactococcus lactis* subsp. *cremoris* NZ9000 was the final host. Detailed plasmid construction used in our project is below (Table 2).

Table 2 Plasmid construction used in our project.

| Name | Description |
| pMG36e | pWV01-based expression vector carrying the strong lactococcal promoter P32; Emr |
| pCAB01 | pMG36e, SmPAL-ScCCL-AtCCR |
| pBH99 | pMG36e, bacteriocin biosynthesis cluster |
| pGBP | pMG36e, gbpC expression gene, sfgfp(Bs) |

**Cinnamaldehyde biosynthesis gene plasmid**

Experiment

The pMG36e (BBa\_K4019005), the shuttle vector, was provided by Yamamoto Lab, Tokyo Institute of technology. *E. coli* JM109 was used for pMG36e maintenance. The pMG36e was linearized by Inverse Polymerase Chain Reaction (PCR). The product was purified by Monarch® PCR & DNA Cleanup Kit (5 μg)(New England Biolabs, Inc.). The three gene fragments of the cinnamaldehyde biosynthetic gene, phenylalanine ammonia lyase (BBa\_K4019001), 4-coumarate: CoA ligase (BBa\_K4019002), Cinnamoyl-CoA reductase (BBa\_K1129005), was synthesized by IDT Inc., they have homologous sequence each other at both ends. The three genes were amplified by PCR and purified by Monarch® PCR & DNA Cleanup Kit (5 μg)(New England Biolabs Inc.). All PCR were performed using a T100 Thermal Cycler (Bio-Rad), with PrimeStar Max DNA Polymerase (TaKaRa).

The purified products of the three gene fragments and linearized vector were assembled by NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs, Inc.)(Fig. 1a,b). After reacting, the mixture was transformed to *E. coli DH5α* competent cells(TaKaRa) and spread 100µL on a LB plate containing 100 mg/L Erythromycin. The rest of the mixture was also used insert check PCR as a template. Insert check PCR is explained below(Fig. 1a,b).The plate was incubated overnight at 38℃. The next day, picking individual isolated colonies from the plate, they are inoculated with another LB plate containing 100 mg/L Erythromycin and stored at room temperature. After the colony was sufficiently proliferated enough, each colony was fermented in 4 mL LB liquid medium containing 100 mg/L Erythromycin. Each medium is treated by FastGene Plasmid Mini Kit (Nippon Genetics Co., Ltd.) to extract a recombinant plasmid, pCAB01, to check if fragments and vector were assembled properly (Fig. 3c).

Fig3. The three gene fragments (phenylalanine ammonia lyase, 4-coumarate: CoA ligase, Cinnamoyl-CoA reductase was cloned to pMG36e:

![](https://static.igem.org/mediawiki/2021/2/27/T--TokyoTech--Exp._Fig._1a_pCAB01.jpg)

(a) Construction of pCAB01.

![](https://static.igem.org/mediawiki/2021/5/57/T--TokyoTech--Exp._Fig._1b.png)

(b) pCAB was assembled and checked by insert check PCR. In the insert check PCR, the Forward and Reverse primer was designed on the Linearized vector both end outward. If insert fragments were cloned, The 4746 bp fragment would be amplified. If not, 466bp fragment would be amplified. lane1: pCAB01, lane2: Negative control.

![](https://static.igem.org/mediawiki/2021/6/68/T--TokyoTech--Exp._Fig._1c.png)

(c) pCAB01 was assembled and checked if transformation succeeded. The recombinant plasmid, pCAB01 was 7886 bp. These plasmids were considered the Covalently Closed Circular (CCC) form. The CCC form was run faster than the Linear form[1].

**Bacteriocin biosynthesis gene plasmid**

Bacteriocin gene cluster was amplified by polymerase chain reaction(PCR) with primers. *Lactiplantibacillus pentosus* H99 grown in culture(Difco Lactobacilli MRS Broth) was used as a template. The pMG36e and bacteriocin gene cluster were digested with restriction enzymes SacⅠ/PstⅠ. The pMG36e was purified by gel extraction and the bacteriocin gene cluster was purified by phenol-chloroform extraction. The purified products were assembled by ligation reaction and transformed into *E.coli* DH5α competent cells. Transformants were spread on a LB plate containing 600 µg/mL Erythromycin. On the next day, colonies were picked up and cultivated on the plate and in the 1 mL LB medium. Cloning success was checked by colony PCR and subcloned plasmid was extracted by miniprep.

**Glucan-binding protein C expression plasmid**

 Glucan-binding protein C was amplified by polymerase chain reaction(PCR) with primers. Crushed Streptococcus mutans which was grown in culture(Bacto Tryptic Soy Broth) was used as a template. The pMG36e and gbpC amplicon were digested with restriction enzymes XmaⅠ/XbaⅠ. The rest of the process is the same with the cloning of bacteriocin biosynthesis gene cluster.

Fig4. Transformants cultivating plates(Em 600 µg/mL)

![](https://static.igem.org/mediawiki/2021/2/24/T--TokyoTech--transformant_gbpCbc.png)

(a) gbpC cloned E.coli (b) bacteriocin synthetic gene cluster cloned E.coli

**Transformation of Lactococcus lactis.**

 Transformants of *E.coli* which were confirmed by colony PCR or miniprep were cultured, and plasmids were extracted. The recombinant plasmid was then introduced into *Lactococcus lactis* subsp. *cremoris* NZ9000 by electroporation(1500V). The transformants were spread on MRS plates containing 4µg/mL erythromycin, and colonies appeared over 4-6 days.

**Functional analysis**

 Before constructing the whole system, we analyzed the expression and function of cinnamaldehyde biosynthesis gene, bacteriocin biosynthesis gene and glucan-binding protein C.

**Cinnamaldehyde biosynthesis / Bacteriocin biosynthesis gene**

To investigate whether the transformants have antibacterial activity, we performed spot test assay and viable/dead bacterial evaluation.

1. Spot test assay

We layered soft agar with *S.mutans* as indicator bacteria on LB plate, and transformants with cinnamaldehyde and bacteriocin synthesis gene which was washed and suspended in PBS were spotted on the plate. We hoped that transformants would make inhibitory circles, but the *S.mutans* grew so slowly that we could not successfully see any antibacterial activity.

Fig5. Spot assay

![](https://static.igem.org/mediawiki/2021/6/65/T--TokyoTech--spotassay.jpg)

(a)*Lactococcus lactis* subsp. *cremoris* NZ9000 (b)Transformants with bacteriocin biosynthesis gene
 (c)*E. coli* JM109 (d)Transformants with cinnamaldehyde biosynthesis gene

2. Viable/Dead bacterial evaluation
After CFDA staining of mutans bacteria fixed on dextran, recombinants which were washed and suspended in PBS were added, incubated, washed and PI stained. However, there was not much difference from the host used as a control. The bacteria were washed to remove antibiotics in the medium, but it is thought that the addition of medium was necessary because substrates are required for the production of antibacterial substances. There was also the problem that *S.mutans* was detached from the plate after repeated washing, or that bacteria other than mutans were stained. Although the evaluation of antimicrobial activity did not go well, we would like to confirm the inhibitory effect of biofilm formation by conducting a biofilm assay.

**Glucan-binding protein C**

In order to evaluate the binding of the GbpC expression strain to glucan, we attempted to perform a dextran binding assay. Since the gbpC-expressing strain of recombinant *L.lactis* could not be cultured well, we tried to see if it would work with *S. mutans*, which expresses gbpC on its surface. Dextran was fixed on an immunoplate, and the culture medium of the *S.mutans* was added to it, incubated, washed, and CFDA staining was performed. A large number of *S. mutans* were observed in comparison to those using BSA instead of dextran as a control, confirming that *S. mutans* has dextran-binding properties.

Fig.6 Dextran binding assay

![](https://static.igem.org/mediawiki/2021/6/69/T--TokyoTech--dexw.jpg)

(a) *S.mutans* on the dextran fixed plate

![](https://static.igem.org/mediawiki/2021/1/13/T--TokyoTech--bsa.jpg)

(b)*S.mutans* on the BSA fixed plate

**Experimental difficulties**
・Inverse PCR of pMG36e
We planned to prepare the linearized vector used construction of pCAB01 by Inverse PCR. We designed a proper primer, however, the vector was not amplified. We considered that this reason was high plasmid template concentration and non-specific primer hybridization. Therefore, We conducted improved experiments that plasmid template concentration was diluted gradually and the sample loaded in the Thermal cycler at first step temperature, 98℃.

・Double digestion by Xma1/Xba1
The shuttle vector we used had fewer restriction enzyme sites than the general vector for E. coli, and our options were limited except for the sites included in the inserted gene. Therefore, we decided to use Xma1 and Xba1 for the cloning of gbpC. However, either or both of these had poor cleavage efficiency, and it was not possible to perform complete double-strand breaks under normal reaction conditions, so we repeated cleavage and purification twice before performing the ligation reaction.

・Concentration of erythromycin
The pMG36e vector incorporated the erythromycin resistance gene as a marker, but at the concentration described in the paper[2], some non-transformants proliferated, making it difficult to select transformants. Therefore, the concentration of erythromycin was adjusted to achieve the optimal concentration for screening, so that screening could be performed correctly.

**Future works**

**Analysis of Cinnamaldehyde production**
The colony which maintained pCAB01 is dispersed LB liquid medium and incubated at 38℃. The strain is spined down and collected supernatant. The supernatant is added to ethyl acetate, a one to one ratio between ethyl acetate and supernatant. and then the ethyl acetate phase is collected and analyzed by High Performance Liquid Chromatography (HPLC).

Fig. 7 HPLC chromatogram of extract from medium mixed cinnamaldehyde. The retention time of cinnamaldehyde was 14.974 min. It indicated that the amount of cinnamaldehyde can be measured using the above method. We would like to measure the amount of cinnamaldehyde by our recombinant *E.coli*.

![](https://static.igem.org/mediawiki/2021/a/ac/T--TokyoTech--Exp.Futureworks.png)

Finally, pCAB01 is transformed from recombinant *E.coli* to L.lactis and measure the ability to diffuse cinnamaldehyde.

References

[1] Hintermann, G., Fischer, H. M., Crameri, R. & Hütter, R. Simple procedure for distinguishing CCC, OC, and L forms of plasmid DNA by agarose gel electrophoresis. *Plasmid* 5, 371–373 (1981).

[2]M van de Guchte, J M van der Vossen, J Kok, G Venema, Construction of a lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. *Applied and Environmental Microbiology*, 1989, 55(1): 224-228

* [Home](https://2021.igem.org/Team%3ATokyoTech)
* [Project](https://2021.igem.org/Team%3ATokyoTech/Background)
* [Wet Lab](https://2021.igem.org/Team%3ATokyoTech/Design)
* [Dry Lab](https://2021.igem.org/Team%3ATokyoTech/Model)
* [Human Practice](https://2021.igem.org/Team%3ATokyoTech/Human_Practices)
* [Team](https://2021.igem.org/Team%3ATokyoTech/Team)

Copyright© iGEM TokyoTech 2021, All rights reserved

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:TokyoTech/Experiments

<!doctype html>

# [![teamlogo](https://static.igem.org/mediawiki/2021/d/d1/T--tokyotech--logo.jpg)](https://2021.igem.org/Team%3ATokyoTech)

* [HOME](https://2021.igem.org/Team%3ATokyoTech)
* [Project](https://2021.igem.org/Team%3ATokyoTech/Background)
  + [Background](https://2021.igem.org/Team%3ATokyoTech/Background)
  + [Despriciton](https://2021.igem.org/Team%3ATokyoTech/Description)
  + [Contribution](https://2021.igem.org/Team%3ATokyoTech/Contribution)
  + [Implementation](https://2021.igem.org/Team%3ATokyoTech/Implementation)
* [Wet Lab](https://2021.igem.org/Team%3ATokyoTech/Design)
  + [Design](https://2021.igem.org/Team%3ATokyoTech/Design)
  + [Experiments](https://2021.igem.org/Team%3ATokyoTech/Experiments)
  + [Parts](https://2021.igem.org/Team%3ATokyoTech/Parts)
* [Dry Lab](https://2021.igem.org/Team%3ATokyoTech/Model)
  + [Modeling](https://2021.igem.org/Team%3ATokyoTech/Model)
* [Human Practices](https://2021.igem.org/Team%3ATokyoTech/Human_Practices)
  + [Specialists](https://2021.igem.org/Team%3ATokyoTech/Specialists)
  + [Eduication](https://2021.igem.org/Team%3ATokyoTech/Education)
  + [Team Building](https://2021.igem.org/Team%3ATokyoTech/TeamBuilding)
  + [Deliver Class](https://2021.igem.org/Team%3ATokyoTech/DeliveryClass)
  + [BioSafety](https://2021.igem.org/Team%3ATokyoTech/BioSafety)
* [Team](https://2021.igem.org/Team%3ATokyoTech/Team)
  + [Members](https://2021.igem.org/Team%3ATokyoTech/Team)
  + [Judging Form](https://igem.org/2021_Judging_Form?id=4019)
  + [Collaborations](https://2021.igem.org/Team%3ATokyoTech/Collaborations)
  + [Attributions](https://2021.igem.org/Team%3ATokyoTech/Attributions)

Experiments

**Antimicrobial activity assay**

To evaluate antimicrobial activity of cinnamaldehyde and bacteriocin against *Streptococcus mutans*, we determined Minimum Inhibitory Concentration(MIC) of them.

**Broth Dilution Method**

 We made two-fold dilutions of antimicrobial agents\* on the 96-well plate and added TSB and overnight culture of *S.mutans* and *Listeria Monocytogenes*(Control) each well.

\*We purchased cinnamaldehyde from Wako, and bacteriocin was purified from broth of H99 and quantified concentration by OPA.

Fig. 1 MIC of cinnamaldehyde and bacteriocin

![](https://static.igem.org/mediawiki/2021/2/2f/T--TokyoTech--MIC.jpg)

The critical concentrations for antimicrobial activity were 3-fold dilution for cinnamaldehyde and the initial concentration for bacteriocin.
\*n was added no antibacterial substances as a negative control.

Table.1 MIC of cinnamaldehyde and bacteriocin

|  | Initial concentration | MIC against *S.mutans* |
| Cinnamaldehyde | 4.00 mg/mL | 0.500 mg/mL |
| Bacteriocin | 0.062 mM | 0.062 mM |

**Measurement of transformation efficiency**

 To confirm that our backbone plasmid works in *L.lactis*, we measured transformation efficiency. *Lactococcus lactis* subsp. cremoris NZ9000 was harvested in MRS medium and collected by centrifugation. Collected cells are washed with HEPES,sucrose buffer and suspended. The pMG36e was transformed into *L.lactis* by electroporation at 1500V/2000V/2500V. Transformants are spread on MRS agar plates with and without 4 µg/mL erythromycin.
Colonies could be seen on the plates of 1500 V. Colony forming units was calculated as follows.

\[
\ 88 CFU / (17.6\_{ng / \mu L} \times 10\_{\mu L} \times 10^{-3} ) \times \frac{400}{200} = 1000 CFU/\mu g
\]

Fig. 2 Transformation efficiency

![](https://static.igem.org/mediawiki/2021/d/db/T--TokyoTech--transformant.jpg)

No colonies were observed at 2000 V and 2500 V, but colonies gradually appeared over 2-6 days at 1500 V.

**Gene cloning**

Before building the entire system as a whole, we constructed three functional plasmid, Cinnamaldehyde biosynthesis gene plasmid, Bacteriocin biosynthesis gene plasmid and Glucan-binding protein C expression plasmid.

**Bacterial strains and plasmids**

*E. coli* DH5α was used for primary host of protein expression and production of antibacterial compounds. *Lactococcus lactis* subsp. *cremoris* NZ9000 was the final host. Detailed plasmid construction used in our project is below (Table 2).

Table 2 Plasmid construction used in our project.

| Name | Description |
| pMG36e | pWV01-based expression vector carrying the strong lactococcal promoter P32; Emr |
| pCAB01 | pMG36e, SmPAL-ScCCL-AtCCR |
| pBH99 | pMG36e, bacteriocin biosynthesis cluster |
| pGBP | pMG36e, gbpC expression gene, sfgfp(Bs) |

**Cinnamaldehyde biosynthesis gene plasmid**

Experiment

The pMG36e (BBa\_K4019005), the shuttle vector, was provided by Yamamoto Lab, Tokyo Institute of technology. *E. coli* JM109 was used for pMG36e maintenance. The pMG36e was linearized by Inverse Polymerase Chain Reaction (PCR). The product was purified by Monarch® PCR & DNA Cleanup Kit (5 μg)(New England Biolabs, Inc.). The three gene fragments of the cinnamaldehyde biosynthetic gene, phenylalanine ammonia lyase (BBa\_K4019001), 4-coumarate: CoA ligase (BBa\_K4019002), Cinnamoyl-CoA reductase (BBa\_K1129005), was synthesized by IDT Inc., they have homologous sequence each other at both ends. The three genes were amplified by PCR and purified by Monarch® PCR & DNA Cleanup Kit (5 μg)(New England Biolabs Inc.). All PCR were performed using a T100 Thermal Cycler (Bio-Rad), with PrimeStar Max DNA Polymerase (TaKaRa).

The purified products of the three gene fragments and linearized vector were assembled by NEBuilder® HiFi DNA Assembly Master Mix (New England Biolabs, Inc.)(Fig. 1a,b). After reacting, the mixture was transformed to *E. coli DH5α* competent cells(TaKaRa) and spread 100µL on a LB plate containing 100 mg/L Erythromycin. The rest of the mixture was also used insert check PCR as a template. Insert check PCR is explained below(Fig. 1a,b).The plate was incubated overnight at 38℃. The next day, picking individual isolated colonies from the plate, they are inoculated with another LB plate containing 100 mg/L Erythromycin and stored at room temperature. After the colony was sufficiently proliferated enough, each colony was fermented in 4 mL LB liquid medium containing 100 mg/L Erythromycin. Each medium is treated by FastGene Plasmid Mini Kit (Nippon Genetics Co., Ltd.) to extract a recombinant plasmid, pCAB01, to check if fragments and vector were assembled properly (Fig. 3c).

Fig3. The three gene fragments (phenylalanine ammonia lyase, 4-coumarate: CoA ligase, Cinnamoyl-CoA reductase was cloned to pMG36e:

![](https://static.igem.org/mediawiki/2021/2/27/T--TokyoTech--Exp._Fig._1a_pCAB01.jpg)

(a) Construction of pCAB01.

![](https://static.igem.org/mediawiki/2021/5/57/T--TokyoTech--Exp._Fig._1b.png)

(b) pCAB was assembled and checked by insert check PCR. In the insert check PCR, the Forward and Reverse primer was designed on the Linearized vector both end outward. If insert fragments were cloned, The 4746 bp fragment would be amplified. If not, 466bp fragment would be amplified. lane1: pCAB01, lane2: Negative control.

![](https://static.igem.org/mediawiki/2021/6/68/T--TokyoTech--Exp._Fig._1c.png)

(c) pCAB01 was assembled and checked if transformation succeeded. The recombinant plasmid, pCAB01 was 7886 bp. These plasmids were considered the Covalently Closed Circular (CCC) form. The CCC form was run faster than the Linear form[1].

**Bacteriocin biosynthesis gene plasmid**

Bacteriocin gene cluster was amplified by polymerase chain reaction(PCR) with primers. *Lactiplantibacillus pentosus* H99 grown in culture(Difco Lactobacilli MRS Broth) was used as a template. The pMG36e and bacteriocin gene cluster were digested with restriction enzymes SacⅠ/PstⅠ. The pMG36e was purified by gel extraction and the bacteriocin gene cluster was purified by phenol-chloroform extraction. The purified products were assembled by ligation reaction and transformed into *E.coli* DH5α competent cells. Transformants were spread on a LB plate containing 600 µg/mL Erythromycin. On the next day, colonies were picked up and cultivated on the plate and in the 1 mL LB medium. Cloning success was checked by colony PCR and subcloned plasmid was extracted by miniprep.

**Glucan-binding protein C expression plasmid**

 Glucan-binding protein C was amplified by polymerase chain reaction(PCR) with primers. Crushed Streptococcus mutans which was grown in culture(Bacto Tryptic Soy Broth) was used as a template. The pMG36e and gbpC amplicon were digested with restriction enzymes XmaⅠ/XbaⅠ. The rest of the process is the same with the cloning of bacteriocin biosynthesis gene cluster.

Fig4. Transformants cultivating plates(Em 600 µg/mL)

![](https://static.igem.org/mediawiki/2021/2/24/T--TokyoTech--transformant_gbpCbc.png)

(a) gbpC cloned E.coli (b) bacteriocin synthetic gene cluster cloned E.coli

**Transformation of Lactococcus lactis.**

 Transformants of *E.coli* which were confirmed by colony PCR or miniprep were cultured, and plasmids were extracted. The recombinant plasmid was then introduced into *Lactococcus lactis* subsp. *cremoris* NZ9000 by electroporation(1500V). The transformants were spread on MRS plates containing 4µg/mL erythromycin, and colonies appeared over 4-6 days.

**Functional analysis**

 Before constructing the whole system, we analyzed the expression and function of cinnamaldehyde biosynthesis gene, bacteriocin biosynthesis gene and glucan-binding protein C.

**Cinnamaldehyde biosynthesis / Bacteriocin biosynthesis gene**

To investigate whether the transformants have antibacterial activity, we performed spot test assay and viable/dead bacterial evaluation.

1. Spot test assay

We layered soft agar with *S.mutans* as indicator bacteria on LB plate, and transformants with cinnamaldehyde and bacteriocin synthesis gene which was washed and suspended in PBS were spotted on the plate. We hoped that transformants would make inhibitory circles, but the *S.mutans* grew so slowly that we could not successfully see any antibacterial activity.

Fig5. Spot assay

![](https://static.igem.org/mediawiki/2021/6/65/T--TokyoTech--spotassay.jpg)

(a)*Lactococcus lactis* subsp. *cremoris* NZ9000 (b)Transformants with bacteriocin biosynthesis gene
 (c)*E. coli* JM109 (d)Transformants with cinnamaldehyde biosynthesis gene

2. Viable/Dead bacterial evaluation
After CFDA staining of mutans bacteria fixed on dextran, recombinants which were washed and suspended in PBS were added, incubated, washed and PI stained. However, there was not much difference from the host used as a control. The bacteria were washed to remove antibiotics in the medium, but it is thought that the addition of medium was necessary because substrates are required for the production of antibacterial substances. There was also the problem that *S.mutans* was detached from the plate after repeated washing, or that bacteria other than mutans were stained. Although the evaluation of antimicrobial activity did not go well, we would like to confirm the inhibitory effect of biofilm formation by conducting a biofilm assay.

**Glucan-binding protein C**

In order to evaluate the binding of the GbpC expression strain to glucan, we attempted to perform a dextran binding assay. Since the gbpC-expressing strain of recombinant *L.lactis* could not be cultured well, we tried to see if it would work with *S. mutans*, which expresses gbpC on its surface. Dextran was fixed on an immunoplate, and the culture medium of the *S.mutans* was added to it, incubated, washed, and CFDA staining was performed. A large number of *S. mutans* were observed in comparison to those using BSA instead of dextran as a control, confirming that *S. mutans* has dextran-binding properties.

Fig.6 Dextran binding assay

![](https://static.igem.org/mediawiki/2021/6/69/T--TokyoTech--dexw.jpg)

(a) *S.mutans* on the dextran fixed plate

![](https://static.igem.org/mediawiki/2021/1/13/T--TokyoTech--bsa.jpg)

(b)*S.mutans* on the BSA fixed plate

**Experimental difficulties**
・Inverse PCR of pMG36e
We planned to prepare the linearized vector used construction of pCAB01 by Inverse PCR. We designed a proper primer, however, the vector was not amplified. We considered that this reason was high plasmid template concentration and non-specific primer hybridization. Therefore, We conducted improved experiments that plasmid template concentration was diluted gradually and the sample loaded in the Thermal cycler at first step temperature, 98℃.

・Double digestion by Xma1/Xba1
The shuttle vector we used had fewer restriction enzyme sites than the general vector for E. coli, and our options were limited except for the sites included in the inserted gene. Therefore, we decided to use Xma1 and Xba1 for the cloning of gbpC. However, either or both of these had poor cleavage efficiency, and it was not possible to perform complete double-strand breaks under normal reaction conditions, so we repeated cleavage and purification twice before performing the ligation reaction.

・Concentration of erythromycin
The pMG36e vector incorporated the erythromycin resistance gene as a marker, but at the concentration described in the paper[2], some non-transformants proliferated, making it difficult to select transformants. Therefore, the concentration of erythromycin was adjusted to achieve the optimal concentration for screening, so that screening could be performed correctly.

**Future works**

**Analysis of Cinnamaldehyde production**
The colony which maintained pCAB01 is dispersed LB liquid medium and incubated at 38℃. The strain is spined down and collected supernatant. The supernatant is added to ethyl acetate, a one to one ratio between ethyl acetate and supernatant. and then the ethyl acetate phase is collected and analyzed by High Performance Liquid Chromatography (HPLC).

Fig. 7 HPLC chromatogram of extract from medium mixed cinnamaldehyde. The retention time of cinnamaldehyde was 14.974 min. It indicated that the amount of cinnamaldehyde can be measured using the above method. We would like to measure the amount of cinnamaldehyde by our recombinant *E.coli*.

![](https://static.igem.org/mediawiki/2021/a/ac/T--TokyoTech--Exp.Futureworks.png)

Finally, pCAB01 is transformed from recombinant *E.coli* to L.lactis and measure the ability to diffuse cinnamaldehyde.

References

[1] Hintermann, G., Fischer, H. M., Crameri, R. & Hütter, R. Simple procedure for distinguishing CCC, OC, and L forms of plasmid DNA by agarose gel electrophoresis. *Plasmid* 5, 371–373 (1981).

[2]M van de Guchte, J M van der Vossen, J Kok, G Venema, Construction of a lactococcal expression vector: expression of hen egg white lysozyme in Lactococcus lactis subsp. lactis. *Applied and Environmental Microbiology*, 1989, 55(1): 224-228

* [Home](https://2021.igem.org/Team%3ATokyoTech)
* [Project](https://2021.igem.org/Team%3ATokyoTech/Background)
* [Wet Lab](https://2021.igem.org/Team%3ATokyoTech/Design)
* [Dry Lab](https://2021.igem.org/Team%3ATokyoTech/Model)
* [Human Practice](https://2021.igem.org/Team%3ATokyoTech/Human_Practices)
* [Team](https://2021.igem.org/Team%3ATokyoTech/Team)

Copyright© iGEM TokyoTech 2021, All rights reserved

[![](https://static.igem.org/mediawiki/2021/8/8b/HQ_page_logo.jpg)](https://2021.igem.org)

# Team:TokyoTech/Results

# Results

You can describe the results of your project and your future plans here.

### What should this page contain?

* Clearly and objectively describe the results of your work.
* Future plans for the project.
* Considerations for replicating the experiments.

### Describe what your results mean

* Interpretation of the results obtained during your project. Don't just show a plot/figure/graph/other, tell us what you think the data means. This is an important part of your project that the judges will look for.
* Show data, but remember **all measurement and characterization data must also be on the Part's Main Page on the [Registry](http://parts.igem.org/Main_Page).** Otherwise these data will not be in consideration for any medals or part awards!
* Consider including an analysis summary section to discuss what your results mean. Judges like to read what you think your data means, beyond all the data you have acquired during your project.

### Project Achievements

You can also include a list of bullet points (and links) of the successes and failures you have had over your summer. It is a quick reference page for the judges to see what you achieved during your summer.

* A list of linked bullet points of the successful results during your project
* A list of linked bullet points of the unsuccessful results during your project. This is about being scientifically honest. If you worked on an area for a long time with no success, tell us so we know where you put your effort.

### Inspiration

See how other teams presented their results.

* [2019 Newcastle](https://2019.igem.org/Team%3ANewcastle/Results)
* [2019 Munich](https://2019.igem.org/Team%3AMunich/Results)
* [2019 Tec Chihuahua](https://2019.igem.org/Team%3ATec-Chihuahua/Results)
* [2020 Aalto Helsinki](https://2020.igem.org/Team%3AAalto-Helsinki/Results)
* [2020 GreatBay SCIE](https://2020.igem.org/Team%3AGreatBay_SCIE/Results)
* [2020 Queens Canada](https://2020.igem.org/Team%3AQueens_Canada/Results)